KALV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
KalVista Pharmaceuticals Inc (KALV) does not currently present a strong buy opportunity for a beginner investor with a long-term strategy. While the stock has bullish technical indicators and positive analyst sentiment, the lack of recent news catalysts, insider and hedge fund selling trends, and weak financial performance with consistent net losses suggest caution. Given the user's impatience and unwillingness to wait for optimal entry points, holding off on investment is recommended until stronger positive catalysts emerge.
The technical indicators show a bullish trend with SMA_5 > SMA_20 > SMA_200, a positive MACD histogram (0.0702), and RSI in the neutral zone (59.585). Key support and resistance levels are Pivot: 15.278, R1: 15.996, S1: 14.56, R2: 16.44, S2: 14.116. However, the stock's candlestick pattern suggests an 80% chance of a -1.34% decline in the next day and only a 10.98% chance of a 10.98% increase in the next week.
Analysts have raised price targets significantly, with targets ranging from $29 to $37, and maintain Buy or Outperform ratings. The company's product, Ekterly, shows strong initial performance, and analysts expect it to be a market leader in the hereditary angioedema therapy space.
Hedge funds and insiders are selling heavily, with hedge fund selling up 7382.63% and insider selling up 270.56%. The company has no recent news catalysts, and financials show consistent net losses, with a Q3 2025 net income of -$49.48M. Congress trading data shows no recent activity, and no Intellectia Proprietary Trading Signals are present.
In Q3 2025, revenue remained flat YoY at $13.69M. Net income improved by 70.46% YoY but remains negative at -$49.48M. EPS increased by 9.52% YoY to -0.92. Gross margin remained strong at 91%, but the company is still far from profitability.
Analysts are bullish, with multiple firms raising price targets recently. TD Cowen raised the target to $35, Citizens to $29, H.C. Wainwright to $37, and Needham to $32. Analysts highlight the strong initial performance of Ekterly and its potential to dominate the hereditary angioedema therapy market.
